Novartis To Launch Anti-Diabetic Starlix In February With Firm's 4,000 Reps

Novartis plans to launch its first anti-diabetic, the type 2 diabetes therapy Starlix, in February using its 4,000 U.S. sales reps. Novartis reps target mostly primary-care physicians and will be trained in the anti-diabetic area.